Consistent with this result, flow cytometry analysis showed that the proportion of the proliferation marker Ki67 (CD11b−Ki67+) was reduced in tumor tissues in the HER2 CAR-M group (Fig. 4E). This evidence concerns the gene ERBB2 and neoplasm.